Abstract:Antibody-based therapies are at the forefront of modern medicine, addressing diverse challenges across oncology, autoimmune diseases, infectious diseases, and beyond. The ability to design antibodies with enhanced functionality and specificity is critical for advancing next-generation therapeutics. Recent advances in artificial intelligence (AI) have propelled the field of antibody engineering, particularly through inverse folding models for Complementarity-Determining Region (CDR) sequence design. These models aim to generate novel antibody sequences that fold into desired structures with high antigen-binding affinity. However, current evaluation metrics, such as amino acid recovery rates, are limited in their ability to assess the structural and functional accuracy of designed sequences. This study benchmarks state-of-the-art inverse folding models - ProteinMPNN, ESM-IF, LM-Design, and AntiFold - using comprehensive datasets and alternative evaluation metrics like sequence similarity. By systematically analyzing recovery rates, mutation prediction capabilities, and amino acid composition biases, we identify strengths and limitations across models. AntiFold exhibits superior performance in Fab antibody design, particularly in variable regions like CDRH3, whereas LM-Design demonstrates adaptability across diverse antibody types, including VHH antibodies. In contrast, models trained on general protein datasets (e.g., ProteinMPNN and ESM-IF) struggle with antibody-specific nuances. Key insights include the models' varying reliance on antigen structure and their distinct capabilities in capturing critical residues for antigen binding. Our findings highlight the need for enhanced training datasets, integration of functional data, and refined evaluation metrics to advance antibody design tools. By addressing these challenges, future models can unlock the full potential of AI-driven antibody engineering, paving the way for innovative therapeutic applications.

AI-driven antibody design with generative diffusion models: current insights and future directions

A comprehensive overview of recent advances in generative models for antibodies

Accelerating antibody discovery and design with artificial intelligence: recent advances and prospects

Leveraging Artificial Intelligence to Expedite Antibody Design and Enhance Antibody–Antigen Interactions

Antigen-Specific Antibody Design and Optimization with Diffusion-Based Generative Models for Protein Structures

Unlocking antibody design with generative artificial intelligence

A new era of antibody discovery: an in-depth review of AI-driven approaches

The Application of Machine Learning on Antibody Discovery and Optimization

Guiding diffusion models for antibody sequence and structure co-design with developability properties

Retrieval Augmented Diffusion Model for Structure-informed Antibody Design and Optimization

AI-based IsAb2.0 for antibody design

Benchmarking Inverse Folding Models for Antibody CDR Sequence Design

Antibody-SGM, a Score-Based Generative Model for Antibody Heavy-Chain Design

AI driven B-cell Immunotherapy Design

IgGM: A Generative Model for Functional Antibody and Nanobody Design

In Silico Methods In Antibody Design

Improving Antibody Design with Force-Guided Sampling in Diffusion Models

Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery

Advancing Antibody Engineering through Synthetic Evolution and Machine Learning

Revolutionizing Synthetic Antibody Design: Harnessing Artificial Intelligence and Deep Sequencing Big Data for Unprecedented Advances

In Silico Approaches to Deliver Better Antibodies by Design: The Past, the Present and the Future